Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate Academic Article uri icon

Overview

MeSH Major

  • Abiraterone Acetate
  • Antineoplastic Agents
  • Prostatic Neoplasms, Castration-Resistant
  • Trans-Activators

abstract

  • Both ERG-rearranged and wild-type cancers had a significant improvement in rPFS with abiraterone acetate and prednisone in the COU-AA-302 trial. However, our data suggest that 2+ Edel cancers, accounting for 15% of all mCRPC patients and previously associated with a worse outcome, derived the greatest benefit. Clin Cancer Res; 21(7); 1621-7. ©2015 AACR.

publication date

  • April 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4384987

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-14-1961

PubMed ID

  • 25593303

Additional Document Info

start page

  • 1621

end page

  • 7

volume

  • 21

number

  • 7